Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma

Lenalidomide and pomalidomide are two immunomodulatory medications with the potential to improve outcomes for patients with multiple myeloma; however, a black box warning for venous thromboembolism exists. The purpose of this study was to assess overall adherence to guideline recommendations for anticoagulation therapy with lenalidomide and pomalidomide in multiple myeloma patients. This retrospective study at an ambulatory oncology clinic utilized chart reviews from the calendar years 2013–2016. The primary endpoint was prescription of appropriate anticoagulation upon initiation of therapy based on a list of predetermined risk factors. Secondary endpoints included incidence of deep venous thromboembolism, pulmonary embolism, myocardial infarction, stroke, and major bleed; initial anticoagulant prescribed; and whether or not anticoagulation was prescribed for another disease state. A total of 130 patients met inclusion criteria: 70.8% (n？=？92) and 29.2% (n？=？38) were prescribed lenalidomide and pomalidomide, respectively. A total risk score of two was most common (n？=？54, 41.5%). Aspirin 81？mg oral tablet was prescribed most often (n？=？53, 40.8%), followed by no anticoagulation (n？=？30, 23.1%). Overall, 27 patients (20.8%) were prescribed anticoagulation in accordance with National Comprehensive Cancer Network guidelines. Incidence of deep venous thromboembolism was the most common adverse event (n？=？4, 3.1%), followed by major bleed (n？=？1, 0.8%). No reports of pulmonary embolism, myocardial infarction, or stroke were documented. Overall, a disparity exists between appropriate prescribing of prophylactic anticoagulation and current practice guidelines. However, documentation of thromboembolic events was lower than recorded in previously published literature